Source: https://www.wipo.int/amc/en/domains/decisions/html/2007/d2007-0941.html
Timestamp: 2019-04-25 08:32:39+00:00

Document:
The Complainant is Sanofi-Aventis, Paris, France, represented by Bird & Bird Solicitors, France.
The Respondent is Miranda Kurucescu, Bucuresti, Romania.
The disputed domain name <ambienforyou.biz> is registered with Direct Information Pvt Ltd d/b/a PublicDomainRegistry.com.
The Complaint was filed with the WIPO Arbitration and Mediation Center (the “Center”) on June 26, 2007. On June 29, 2007, the Center transmitted by email to Direct Information Pvt Ltd d/b/a PublicDomainRegistry.com a request for registrar verification in connection with the domain name at issue. On June 30, 2007, Direct Information Pvt Ltd d/b/a PublicDomainRegistry.com transmitted by email to the Center its verification response confirming that the Respondent is listed as the registrant and providing the contact details. The Center verified that the Complaint satisfied the formal requirements of the Uniform Domain Name Dispute Resolution Policy (the “Policy”), the Rules for Uniform Domain Name Dispute Resolution Policy (the “Rules”), and the WIPO Supplemental Rules for Uniform Domain Name Dispute Resolution Policy (the “Supplemental Rules”).
The Center appointed Eduardo Machado as the sole panelist in this matter on July 31, 2007. The Panel finds that it was properly constituted. The Panel has submitted the Statement of Acceptance and Declaration of Impartiality and Independence, as required by the Center to ensure compliance with the Rules, paragraph 7.
The Complainant Sanofi-Aventis is a multinational company present in more than one-hundred countries across five continents.
The group benefits from a large portfolio of high-growth drugs, with eight ‘blockbusters’ pharmaceuticals in 2005: Lovenox, Plavix, Taxotere, Eloxatin, Ambien, Allegra, Lantus and Tritace. It enjoys firmly established positions in seven key fast-growth therapeutic fields: cardiovascular, thrombosis, metabolism, oncology, central nervous system, internal medicine and human vaccines.
Employing approximately 97,181 people worldwide, Sanofi-Aventis has a sales force of 35,030 persons, as well as more than 17,600 research staff with one hundred and twenty-seven projects under development, fifty-six of which are at advanced stages and seventy-one in pre-clinical development.
Sanofi-Aventis is a major player on the pharmaceutical market in the United States. With eight flagship products, the Group consolidated its excellent positioning in major therapeutic areas: cardiovascular, thrombosis, cancer, diabetes, central nervous system, internal medicine, metabolic disorders and vaccines.
The main contributors to growth in 2004 were: Plavix�, still the Group’s best-selling product in the United States with 34% sales growth; Ambien�, up by 21% and keeping its number one position on the hypnotics market; Lovenox�, which again outperformed the market with 20% growth sales.
The Complainant owns a large number of AMBIEN trademarks in more than 50 countries including the US and the European community.
The Complainant and its affiliates, have registered numerous domain names worldwide containing the AMBIEN trademark, for example <ambien.fr>; <ambien.us>; <ambien.co.uk>; <ambien.net>; <ambien.biz>.
The Complainant has filed many complaints before the WIPO, regarding trademark AMBIEN so as to obtain the transfer of the contentious domain names.
The Complainant contends that the disputed domain name is confusingly similar to its AMBIEN trademark. It maintains that the addition of the terms “foryou” and the gTLD “.biz” does not change the overall impression of the designation as being connected to the Complainant, and is designed to cause persons accessing the domain name to mistakenly believe that the disputed domain name has a connection with the Complainant.
(d) the Respondent has not made a bona fide use of the disputed domain name.
The Panel finds that <ambienforyou.biz> is confusingly similar to the AMBIEN marks since the dominant portion of Complainant’s registered marks and of the disputed domain name is “ambien”. The domain name differs from Complainant’s registered AMBIEN marks only in that it contains the terms “foryou”.
The Panel finds that adding generic words to a domain name such as “foryou” is not sufficient to escape the finding of similarity and does not change the overall impression of the designation as being connected to the trademark of the Complainant. In this case the words “for you” do not serve any distinguishing function. Of relevance are the following domain names, which were all held by previous panels to be confusingly similar to the AMBIEN trademark of the Complainant: Sanofi-Aventis v. Helois Lab, WIPO Case No. D2005-0607 (<ambienadvisor.com>); Sanofi-Aventis v. Juntech Inc, WIPO Case No. D2005-0606 (<online-ambien.biz>); Sanofi-Aventis v. Gabe Smith, WIPO case No. D2005-0605 (<buy-ambien-online.net>); Sanofi-Aventis v. Conciergebrain.com, WIPO Case No. D2005-0660 (<ambien-free-shipping.com>,<ambien-overnight.info>, <ambien-overnight.org>, <ambien-pharmacie.net>, <ambien-prescription.org>, <ambien-usa.net>, <ambien-5mg.org>, <cheap-ambien.net>, <cheap-ambien-no-shipping-charge.com>, <cheap-ambien-sleeping-pill.com>, <cheapest-ambien.org>, <lowest-price-ambien.com>, <order-ambien-cheap.com>) and, specially, SANOFI-AVENTIS v. Health Care Marketing Company, WIPO Case No. D 2007-0475 (<ambienforyou.com>).
With respect to paragraph 4(c)(i) of the Policy, there is no evidence that the Respondent, before any notice of the dispute, used or prepared to use the domain name or a name corresponding to the domain name in connection with a bona fide offering of goods or services.
With respect to paragraph 4(c)(ii) of the Policy, there is no evidence that indicates that the Respondent has ever been commonly known by the domain name.
With respect to paragraph 4(c)(iii) of the Policy, the Respondent has not made and is not making a legitimate noncommercial or fair use of the domain name and has not used the domain name, or a name corresponding to it, in connection with a bona fide offering of goods or services. At the time the UDRP complaint was filed, the domain name provided, in part, links to websites that were in direct competition with the Complainant.
Moreover, the domain name as of the date of this decision still resolves to a page that displays links to Complainant’s competitors. This is not a bona fide use. TM Acquisition Corp. v. Sign Cuards a/k/a William Moore, NAF No.FA132439 (finding that the Respondent’s use of complainant’s marks to divert Internet users to a website which displayed a series of links, some of which were links to sites of complainant’s competitors, was not a bona fide offering of goods or services).
A complainant is required to make out an initial prima facie case that the respondent lacks rights or legitimate interests. Once such a prima facie case is made, respondent carries the burden of demonstrating rights or legitimate interests in the domain name. If the respondent fails to do so, a complainant is deemed to have satisfied paragraph 4(a)(ii) of the Policy. Morgan Freeman v. Mighty LLC, WIPO Case No. D2005-0263; Croatia Airlines d.d. v. Modern Empire Internet Ltd., WIPO Case No. D2003-0455; and Belupo d.d. v. WACHEM d.o.o., WIPO Case No. D2004-0110.
The Panel finds in the circumstances of this case that the Respondent registered the domain name in bad faith.
Complainant’s allegations of bad faith are not contested. The trademark registrations of record confirm Complainant’s allegations that it had long been using its AMBIEN marks when the domain name that is the subject of this Complaint was registered. The Panel finds persuasive Complainant’s allegations that the Respondent must have been aware of the Complainant’s rights in the mark and, further that the Respondent knowingly infringed the Complainant’s trademark when it registered the subject domain name.
Under the Policy, it is evidence of bad faith that, “by using the domain name, you have intentionally attempted to attract, for commercial gain, Internet users to your website or other on-line location, by creating a likelihood of confusion with the complainant’s mark as to the source, sponsorship, affiliation, or endorsement of your website or location or of a product or service on your website or location.”, Policy paragraph 4(b)(iv). The Respondent used the Complainant’s known trademark in pharmaceutical industry to attract users to the Respondent’s website where links to Complainant’s competitors are offered. This is evidence of the intention by the Respondent to attract Internet users for commercial gain, by creating a likelihood of confusion with the Complainant’s mark as to the source, sponsorship, affiliation, or endorsement of the Respondents’ website or of a product or service on the Respondents’ website.
At the time the Complaint was filed and at the time of this Decision, the domain name resolves to a page that offers visitors links to sites of other companies, including Complainant’s competitors. Staples, Inc., Staples The Office Superstore, Inc., Staples Contract and & Commercial, Inc. v. John Morgan, WIPO Case No. D2004-0537 (“the Panel is persuaded that Respondent’s registration and use of the disputed domain name for re-directing Internet users, particularly customers and potential customers of Complainants, from Complainants’ website to the website of OfficeMax, a company which directly competes with Complainants, constitutes bad faith and use. Prior WIPO UDRP decisions also support this conclusion.”). See also Edmunds.com, Inc. v. Ult. Search, Inc., WIPO Case No. D2001-1319 (“registration and use of a domain name to redirect Internet users to websites of competing organizations constitutes bad faith registration and use under the Policy.”).
Accordingly the Panel finds that the Complainant has made out bad faith registration and use of the domain name by the Respondent.
For all the foregoing reasons, in accordance with paragraphs 4(i) of the Policy and 15 of the Rules, the Panel orders that the domain name, <ambienforyou.biz> be transferred to the Complainant.

References: v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v.